Communiqués Chugai Pharmaceutical Co., Ltd

Actions

4519

JP3519400000

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 12/06/2024			Varia. 5j.	Varia. 1 janv.
4 966 ^JPY	-0,24 %		+3,16 %	-7,04 %

11/06	Le Nikkei japonais progresse grâce aux actions américaines et aux actions de poids lourds du secteur des semi-conducteurs	RE
23/05	Les valeurs technologiques soutiennent le Nikkei japonais grâce aux perspectives solides de Nvidia	RE

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Chugai Pharmaceutical : Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System Expedited Transcription at the Medical Institution and for SDV in the Pharmaceutical Company	11/06	PU
Chugai Pharmaceutical : Personnel Changes	29/05	PU
Chugai Pharmaceutical : Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Provide Information on Detection of Copy Number Alterations of Cancer-Related Genes and bTMB Score	27/05	PU
Chugai, NCCH, OMPU and MICIN Start Company-Sponsored Phase I Study in Oncology with a New Decentralized Clinical Trial Structure, Improving access to the clinical trial for patients far from the institution	09/05	AQ
Chugai Pharmaceutical : Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan	26/04	PU
Chugai Announces 2024 1st Quarter Results	25/04	AQ
Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024)	24/04	PU
Chugai Pharmaceutical : F. Hoffmann-La Roche Announces First Quarter Sales 2024	24/04	PU
Chugai Pharmaceutical Co., Ltd. - Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks	15/04	AQ
Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Earthquake off the Eastern Coast of Taiwan	10/04	AQ
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer	28/03	AQ
Chugai Pharmaceutical : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan	28/03	PU
Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Associated with Retinal Vein Occlusion	27/03	AQ
Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials	27/03	AQ
Chugai Obtains Regulatory Approval for 'Piasky 340mg' for Paroxysmal Nocturnal Hemoglobinuria in Japan	27/03	AQ
Chugai Pharmaceutical : Finance Report (Jan-Dec 2023) (Posted on March 28)	25/03	PU
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Selpercatinib for RET Fusion-Positive Solid Tumors	01/03	AQ
Chugai Pharmaceutical - Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Phase I study for Relapsed and Refractory Follicular Lymphoma	09/02	AQ
Chugai Pharmaceutical - Crovalimab Approved in China as the First Country, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria	09/02	AQ
Chugai Awarded Highest A-Rating by CDP in Climate Change and Water Security	08/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Chugai Pharmaceutical Co., Ltd

Actions

4519

JP3519400000

Communiqués

Filtres